The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | The ongoing Phase III ELRISE trial: exploring elritercept in LR-MDS treatment
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the potential of elritercept, a novel activin receptor ligand trap, in lower-risk myelodysplastic syndromes (LR-MDS). Prof. Santini highlights encouraging Phase II activity and the ongoing Phase III ELRISE trial (NCT07422480), suggesting that elritercept may improve on the limitations observed with luspatercept in the Phase III COMMANDS study (NCT03682536). This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Elritercept is a new drug. It’s a ligand trap for Activin A receptor, so differently from luspatercept, it has a broader target and especially Activin A is involved in inflammation and is signaling for inflammation in MDS. Therefore, we believe that this drug could be overcoming some of the limits of luspatercept. This Phase II study showed indeed activity of this drug that is very well tolerated...
Elritercept is a new drug. It’s a ligand trap for Activin A receptor, so differently from luspatercept, it has a broader target and especially Activin A is involved in inflammation and is signaling for inflammation in MDS. Therefore, we believe that this drug could be overcoming some of the limits of luspatercept. This Phase II study showed indeed activity of this drug that is very well tolerated. So there are now two studies ongoing with this drug. One is comparing, it’s the Elrise trial, it’s comparing elritercept to ESAs in patients who are transfusion dependent. The other one is a sort of medalist, but including all the patients with MDS without any distinction on RS negative and RS positive, and is comparing elritercept to placebo. So I think that we have a potent agent that could improve the results that we already know for luspatercept. It’s a different drug, different target, so we will wait and see.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
